MedPath

Detection of Bony Metastases: Preliminary Study of 18F-Fluoride Positron Emission Tomography/Computed Tomography (PET/CT)

Not Applicable
Recruiting
Conditions
Detection of bony metastasis
Cancer - Bone
Registration Number
ACTRN12609000120279
Lead Sponsor
ational Science Council, Taiwan
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria

1. patients with histological diagnosis of breast cancer, head and neck cancer, lung cancer, gynecological cancer, genitourinary cancer, or colorectal cancer
2. high risk of or suspicious/equivocal findings for bony metastasis by conventional studies

Exclusion Criteria

1. Patients with more than one type of cancer
2. patients with pregnancy or breast-feeding

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The presence or absence of bony metastasis as assessed by histological proof and/or clinical follow-up by the attending professional oncologist at out-patient clinic every 3 months with the aid of related imaging examinations such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and traditional bone scan (which is different from the 18F-Fluoride Positron Emission Tomography/Computed Tomography as described in the intervention field) at the attending professional oncologist's discretion[This outcome will be assessed every 3 months post-intervention until 1 year for each participant (this outcome is not measured at baseline)]
Secondary Outcome Measures
NameTimeMethod
Overall survival as assessed by questionnaires[On a yearly basis until death];Clinical impact (treatment change due to 18F-Fluoride PET/CT) as assessed by surveys for the professional oncologists for all participants[after one year of follow-up for each participant]
© Copyright 2025. All Rights Reserved by MedPath